The estimated Net Worth of Capital Management, Llcra C... is at least $73.1 Milione dollars as of 13 April 2009. Capital C owns over 1,184 units of Biospecifics Technologies stock worth over $73,111,969 and over the last 16 years Capital sold BSTC stock worth over $0.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Capital C BSTC stock SEC Form 4 insiders trading
Capital has made over 5 trades of the Biospecifics Technologies stock since 2008, according to the Form 4 filled with the SEC. Most recently Capital bought 1,184 units of BSTC stock worth $21,774 on 13 April 2009.
The largest trade Capital's ever made was buying 10,845 units of Biospecifics Technologies stock on 13 March 2009 worth over $206,923. On average, Capital trades about 6,664 units every 22 days since 2008. As of 13 April 2009 Capital still owns at least 825,844 units of Biospecifics Technologies stock.
You can see the complete history of Capital C stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Insiders trading at Biospecifics Technologies
Over the last 33 years, insiders at Biospecifics Technologies have traded over $67,860,045 worth of Biospecifics Technologies stock and bought 7,761,661 units worth $656,708,120 . The most active insiders traders include Capital Management, Llc Kol..., International Plc Endo e Max Link. On average, Biospecifics Technologies executives and independent directors trade stock every 73 days with the average trade being worth of $6,538,649. The most recent stock trade was executed by International Plc Endo on 2 December 2020, trading 7,344,955 units of BSTC stock currently worth $650,028,518.
What does Biospecifics Technologies's logo look like?
Complete history of Capital C stock trades at Biospecifics Technologies
Biospecifics Technologies executives and stock owners
Biospecifics Technologies executives and other stock owners filed with the SEC include:
-
Jennifer Chao,
Independent Chairman of the Board -
Michael Schamroth,
Independent Director -
Paul Gitman,
Independent Director -
Mark Wegman,
Director -
Toby Wegman,
Director -
Sarah McCabe,
Stern Investor Relations -
Michael Sherman,
Independent Director -
Corey Fishman,
Independent Director -
Alex Monteith,
Senior Vice President and Chief Business Officer -
Patrick Hutchison,
Chief Financial Officer -
Joseph Truitt,
Chief Executive Officer, Director -
Jeffrey Kenneth Vogel,
-
Jyrki Mattila,
Director -
Thomas Wegman,
President -
Of Edwin H. Wegman Estate,
10% owner -
Patrick M Caldwell,
Principal Financial Officer -
Partners Lp Bio,
10% owner -
Albert Horcher,
-
Lawrence Dobroff,
CFO -
Max Link,
Director -
Henry Morgan,
Director -
George M Gould,
Director -
Matthew Geller,
Director -
Capital Management, Llc Kol...,
-
Capital Management, Llcra C...,
-
Capital Management, Llcaldr...,
-
Capital Management, Llc Kol...,
-
Capital Management, Llcra C...,
-
J Kevin Buchi,
Chief Executive Officer -
International Plc Endo,
10% owner